Day One Reports Second Quarter 2023 Financial Results and Co

Results from FIREFLY-1 demonstrate overall response rate of 67% and clinical benefit rate of 93% in 69 heavily pretreated Response Assessment Neuro-Oncology High-Grade Glioma evaluable patients...

Related Keywords

California , United States , Australia , Brisbane , Queensland , Canada , American , Jeremy Bender , Laura Cooper , Drug Administration , Exchange Commission , Day One Biopharmaceuticals Inc , Morgan Stanley , European Commission , Company On Linkedin Or Twitter , American Society Of Clinical Oncology , Head Of Communications , Clinical Oncology , New Drug Application , One Biopharmaceuticals , Day One , Response Assessment , Pediatric Neuro Oncology Low Grade Glioma , Independent Review Committee , Hematology Conference , Pacgrow Healthcare Conference , Annual Global Healthcare Conference , Breakthrough Therapy , Rare Pediatric Disease , Orphan Drug , Private Securities Litigation Reform Act , Sci Advisors , Markets ,